Given that access to ophthalmologists can be a significant bottleneck for patients, it is acceptable and practical for routine monitoring of mirvetuximab-related ocular side effects to be managed by optometrists. This pragmatic approach improves accessibility while ensuring patient safety.

While the antibody-drug conjugate (ADC) Tivdac offers a new treatment avenue, it introduces significant logistical hurdles. The requirement for a specialist eye exam at every single visit creates a major access barrier for clinics without integrated ophthalmology services, highlighting how non-clinical factors can limit the real-world application of effective drugs.

This is a crucial concept for predicting ADC toxicities. ADCs with a topoisomerase payload (like TDXD) cause nausea and myelosuppression, while those with a tubulin inhibitor payload (like MERV) cause neuropathy and ocular issues.

For ovarian cancer patients experiencing significant ocular side effects from the ADC mervituximab, switching the dosing schedule from every three weeks to every four weeks can resolve the toxicity by allowing an extra week for recovery.

Nurses can proactively educate patients that if ocular side effects occur, they will likely manifest around the second cycle, between days 10 and 14. This specific timing helps manage patient anxiety and ensures prompt reporting and intervention.

When managing ocular toxicity from the ADC mirvetuximab, clinicians advocate for delaying the subsequent dose to allow the cornea to heal naturally. This approach is often preferred over an immediate dose reduction, which might unnecessarily compromise the treatment's efficacy.

The onset of ocular symptoms from mervituximab is highly predictable, almost always starting between days 10 and 14 of the second treatment cycle. Proactively warning patients about this specific timeline can reduce their anxiety if and when symptoms appear.

The ocular toxicity seen with the folate-targeted ADC mirvetuximab is not due to folate receptors in the eye. It is theorized to be caused by micropinocytosis, an alternative mechanism where the drug is non-specifically taken up by normal corneal cells, representing an off-target, off-tumor toxicity.

Despite being advanced targeted therapies, TROP2-directed ADCs present complex safety profiles. Oncologists must manage classic chemotherapy side effects like nausea and cytopenias alongside unique, serious toxicities including stomatitis, ocular issues, and potentially fatal interstitial lung disease, requiring specialized patient monitoring and counseling.